Search results - 11 results
Interim analysis of COVID-19 vaccine effectiveness against hospitalisation and death using electronic health records in six European countries
a monthly basis, using a study period covering an eight-week follow-up period. Each month the study period was shifted forward to the following month. Country estimates were then pooled together. The study ...
Factors underlying COVID-19 booster vaccine uptake among adults in Belgium
COVID-19 infection history. RESULTS: A binomial regression model was used with having received the first or second booster as outcome and age, sex, region of residence and infection history as fixed ...
Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.
using electronic health registries (EHR), between October 2021 and November 2022, in community-dwelling residents aged 65-79 and ≥80 years in six European countries. METHODS: EHR linkage was used to ...
Characterisation of tetanus monoclonal antibodies as a first step towards the development of an in vitro vaccine potency immunoassay.
antigen. In this paper we report the results of the comprehensive characterisation of a panel of mAbs against tetanus with a view to select antibodies that can be used for development of an in vitro potency ...
Characterisation of diphtheria monoclonal antibodies as a first step towards the development of an in vitro vaccine potency immunoassay.
Volume 69 (2021) Keywords: Antibodies, Monoclonal Diphtheria Diphtheria Toxoid Immunoassay Vaccine Potency Abstract: Immunoassays are used for routine potency assessment of several vaccines, in some cases ...
Regulatory panel discussion. An interactive panel discussion with key authoritative figures from various European regulatory agencies focusing on the regulation of the biologics industry.
Affect an challenge CHALLENGES Discussion European Industries Industry ON production regulation Regulatory use Service: Qualité des vaccins et produits sanguins Kwaliteit van vaccins en bloedproducten ...
Regulatory issues regarding manufacture and control of vaccine adjuvants. The EU situation.
Public-health Quality Receptor Regulatory Requirements response Responses situation specific Stimulation study TESTING Type uptake use vaccine vaccines VIRUS WHO world World Health World Health Organization ...
Cloning of the gene encoding a 22-kilodalton cell surface antigen of Mycobacterium bovis BCG and analysis of its potential for DNA vaccination against tuberculosis.
p.1040-7 (2000) Keywords: Animals Antigens, Bacterial BCG Vaccine Cloning, Molecular Cytokines mice Mice, Inbred BALB C Mice, Inbred C57BL Molecular Weight Vaccines, DNA Abstract: Using spleen cells from ...
Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A.
can confer protection in a rigorous challenge model using a highly virulent human clinical isolate of M. tuberculosis (CSU37). This challenge model appears able to discriminate between DNA vaccines of ...
Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex.
lungs from B6 mice, subsequently challenged. Therefore, this technique may be useful for the definition of protective antigens of M. tuberculosis and the development of a more effective ...